I think its misunderstood on here what big supporters APAC have been of OncoSil. If you review scientific literature and financial reports you can see APAC were early adopters and independently were running excellent studies like these supporting the product. RAH has given many positive presentations on the product over the years at conferences.
If manufacture in Australia manages to bring down COGs of OncoSil that is excellent but reading between the lines of the FY24 financial report it looked like OncoSil cut off support of APAC then despite it making $250k in FY23. I imagine it will be difficult to repair the bridges they have burnt by doing this.
Ann: OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes, page-14
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.020(1.80%) |
Mkt cap ! $20.51M | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $19.98K | 18.08K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3196 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 3598 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| OSL (ASX) Chart |